Cytokinetics Historical Income Statement

CYTK
 Stock
  

USD 47.57  0.27  0.57%   

Historical analysis of Cytokinetics income statement accounts such as Interest Expense of 17.7 M, Operating Expenses of 277 M or Preferred Dividends Income Statement Impact of 1.5 M can show how well Cytokinetics performed in making a profits. Evaluating Cytokinetics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cytokinetics's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Cytokinetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cytokinetics is a good buy for the upcoming year.
Continue to Trending Equities.
  
Refresh

Cytokinetics Net Income

(220.98 Million)

Share

About Cytokinetics Income Statement Analysis

Cytokinetics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cytokinetics shareholders. The income statement also shows Cytokinetics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cytokinetics Income Statement Chart

Cytokinetics Income Statement is one of the three primary financial statements used for reporting Cytokinetics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cytokinetics revenue and expense. Cytokinetics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million

Consolidated Income

The portion of profit or loss for the period; net of income taxes; which is attributable to the consolidated entity; before the deduction of Net Income Available to Non-controlling Interests.

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding [TaxExp] and Interest Expense back to Net Income.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Cytokinetics financial statement analysis. It represents the amount of money remaining after all of Cytokinetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends Income Statement Impact.

Net Income Common Stock

The amount of net income (loss) for the period due to common shareholders. Typically differs from Net Income to the parent entity due to the deduction of Preferred Dividends Income Statement Impact.

Operating Income

Operating Income is the amount of profit realized from Cytokinetics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cytokinetics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Operating income is a measure of financial performance before the deduction of Interest Expense; [TaxExp] and other Non-Operating items. It is calculated as Gross Profit minus Operating Expenses.

Revenues

Revenues refers to the total amount of money received by Cytokinetics for goods sold or services provided during a certain time period. It also includes all of Cytokinetics sales as well as any other increase in Cytokinetics equity.Revenues are reported on Cytokinetics income statement and calculated before any expenses are subtracted. Amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.
Most accounts from Cytokinetics income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million
 2019 2020 2021 2022 (projected)
Revenues USD26.87 M55.83 M70.43 M59.29 M
Revenues26.87 M55.83 M70.43 M59.29 M

Cytokinetics income statement Correlations

Cytokinetics Account Relationship Matchups

Cytokinetics income statement Accounts

201720182019202020212022 (projected)
Consolidated Income(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Earning Before Interest and Taxes EBIT(124.77 M)(102.49 M)(115.07 M)(111.33 M)(198.87 M)(204.11 M)
Earning Before Interest and Taxes USD(124.77 M)(102.49 M)(115.07 M)(111.33 M)(198.87 M)(204.11 M)
Gross Profit13.37 M31.5 M26.87 M55.83 M70.43 M59.29 M
Interest Expense3.02 M3.8 M6.62 M15.96 M16.44 M17.74 M
Net Income(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Net Income Common Stock(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Net Income Common Stock USD(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Operating Expenses126.76 M120.42 M125.73 M149.77 M256.74 M277.01 M
Operating Income(113.4 M)(88.92 M)(98.87 M)(93.94 M)(186.31 M)(191.22 M)
Revenues13.37 M31.5 M26.87 M55.83 M70.43 M59.29 M
Revenues USD13.37 M31.5 M26.87 M55.83 M70.43 M59.29 M
Research and Development Expense90.3 M89.14 M86.12 M96.95 M159.94 M172.56 M
Selling General and Administrative Expense36.47 M31.28 M39.61 M52.82 M96.8 M104.45 M
Weighted Average Shares49.4 M54.42 M57.58 M64.52 M76.89 M65.44 M
Weighted Average Shares Diluted49.4 M54.42 M57.58 M64.52 M76.89 M65.58 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Efficient Frontier Now

   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.2 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.